Navigation Links
Study Counters Warnings on Quit-Smoking Drug
Date:10/2/2009

No clear evidence found that Chantix has dangerous side effects, say UK researchers,,

FRIDAY, Oct. 2 (HealthDay News) -- The smoking cessation drug varenicline (Chantix) does not increase the risk for self-harm or depression, according to a new British study.

In July, the U.S. Food and Drug Administration mandated that the drug carry a "black-box warning" on its packaging, indicating that people who use it face increased risk for "serious neuropsychiatric symptoms," including changes in behavior, hostility, agitation, depressed mood, suicidal thoughts and behavior and attempted suicide.

In the new study, British researchers analyzed database information on 80,660 men and women, ages 18 to 95, who were prescribed a smoking cessation product between September 2006 and May 2008. Prescriptions were for varenicline, the antidepressant bupropion (Zyban) or nicotine replacement products, such as a patch, inhaler, gum, tablet or lozenge. People were followed through the period of the prescription and for three months after the date of their last prescription.

No clear evidence emerged that varenicline or bupropion increased the risk for self-harm, suicidal thoughts or depression, the study reported.

However, the researchers added that "the limited power of the study means we cannot rule out either a halving or a twofold increased risk."

They recommended further study of varenicline's effect on suicide risk. They also said that any risks associated with varenicline must be balanced against the long-term health benefits of stopping smoking and the drug's effectiveness as a smoking cessation product.

The study, which had no drug company funding, was published online Oct. 1 in BMJ.

More information

The Tobacco Control Research Branch of the U.S. National Cancer Institute has more on quitting smoking.


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Page: 1 2

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Dennis Thompson ... News) -- Babies born prematurely appear to have a ... they will carry into adulthood, Swedish researchers report. ... 37 weeks, gestation have a raised risk of deep ... by blood clotting in the veins, the researchers noted ...
(Date:7/28/2014)... A new study, published in the July, 2014, ... Cancer Institute by Northwestern Medicine researchers, sheds ... growing popularity of endoscopic resection in the treatment ... the more traditional surgical resection, while more invasive, ... five-year survival rate for patients than endoscopic resection, ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 A young ... to the all-too-often stories in the media today about ... occur in a matter of minutes in a hot ... to the Office of Emergency Medical Services at NHTSA. ... app for smartphones. Realizing that it’s all too easy ...
(Date:7/28/2014)... Irresistible infants have met their match with a darling ... gifting company specializes in homemade chicken noodle soup and creates bundles ... starts with home-from-the-hospital essentials every new parent will love:, ... , 6 cookies , a ladle to ... to heat and eat upon delivery, so parents can relax and ...
(Date:7/28/2014)... Albany, New York (PRWEB) July 28, 2014 ... Transparency Market Research "E-Clinical Solution Software Market- Global Industry ... 2020," the global microfluidic device market was valued at ... grow at a CAGR of 13.8% from 2014 to ... million in 2020. , Globally, the e-clinical solution software ...
Breaking Medicine News(10 mins):Health News:Preemies May Have Higher Risk of Blood Clots, Even as Adults 2Health News:Preemies May Have Higher Risk of Blood Clots, Even as Adults 3Health News:Study helps compare risks of treatments for early esophageal cancer 2Health News:Study helps compare risks of treatments for early esophageal cancer 3Health News:'Precious Cargo' App Released to Help Save Babies from the Dangers of Being Accidentally Left Behind in Hot Cars 2Health News:Spoonful of Comfort Announces "New Baby" Gift Package 2Health News:Global E-Clinical Solution Software Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Health News:Global E-Clinical Solution Software Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Health News:Global E-Clinical Solution Software Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4
... Stereotaxis, Inc.,(Nasdaq: STXS ) today announced ... institutional investors to raise gross proceeds of $20,million through ... separate,concurrent transactions. A portion of the warrants sold will ... warrants would provide an additional,approximately $10 million in gross ...
... about possible outcomes, study finds , , MONDAY, Dec. 29 ... ill patients want doctors to frankly discuss the patient,s prognosis ... , The University of San Francisco Medical Center study, ... Journal of Respiratory and Critical Care Medicine , points out ...
... Calif., Dec. 29 Accuray Incorporated (Nasdaq: ... radiosurgery, announced today that its management is scheduled to ... in New York, on Wednesday, January 7, 2009 at ... the presentation will be available online from the investor ...
... LCAV ) Board of Directors strongly opposes the consent ... that the Company has undertaken a prudent and achievable strategic ... Joffe intervention is a poorly designed effort to take control ... Joffe effort is an undue distraction to the Company that ...
... Directory on Internet - , , ANTHEM, Ariz., ... announced launch of its new web site at http://www.mychoicedentist.com ... in the Phoenix , Arizona, area is proceeding successfully. ... Chris Theotocatos, CEO. "We anticipate expanding this service to almost ...
... Plans New Products and Expanded Services in 2009 , ... ... has reported its seventh consecutive year of revenue growth in 2008, ... demand for media relations and marketing services provided by its HRmarketer ...
Cached Medicine News:Health News:Stereotaxis to Raise $20 Million in Registered Direct Offering of Common Stock and Warrants 2Health News:Stereotaxis to Raise $20 Million in Registered Direct Offering of Common Stock and Warrants 3Health News:Stereotaxis to Raise $20 Million in Registered Direct Offering of Common Stock and Warrants 4Health News:Family Needs to Know When Patient Survival Is Uncertain 2Health News:Accuray Incorporated to Present at 11th Annual Needham Growth Stock Conference 2Health News:LCA-Vision Urges Stockholders to Take No Action Regarding the Joffe Group's Threatened Consent Solicitation 2Health News:Prime Companies Announces Launch of New Dental Web Site 2Health News:Fisher Vista, LLC Reports Seventh Consecutive Year of Revenue Growth and Profitability 2Health News:Fisher Vista, LLC Reports Seventh Consecutive Year of Revenue Growth and Profitability 3
(Date:7/28/2014)... Colo. , July 28, 2014  Array ... financial results for the fourth quarter and ... a conference call to discuss those results ... Chief Executive Officer and Michael Carruthers ... call.Conference Call InformationDate:Tuesday, August 12, 2014Time:9:00 a.m. ...
(Date:7/28/2014)... 28, 2014  Syneron Medical Ltd. (NASDAQ: ... today that its new PicoWay® device has received CE ... colors and pigmented lesions on any skin type. PicoWay ... 532nm and 1064nm wavelengths, which utilizes Syneron,s proprietary PicoWay ... which are trillionths of a second, known as picosecond ...
(Date:7/28/2014)... July 28, 2014  ResMed (NYSE: RMD ... the treatment of sleep-disordered breathing and other chronic respiratory ... Germany against Taiwanese medical device manufacturer APEX ... on APEX WiZARD 210 and 220 masks.  The judgment ... Munich , is appealable, and applies throughout ...
Breaking Medicine Technology:Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 3Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 4ResMed Receives Permanent Injunction against APEX in Germany, Continues Enforcement of Patents in Europe 2
... 2011 K-V Pharmaceutical Company (the "Company") (NYSE: ... of Obstetricians and Gynecologists (ACOG) and Society for ... and ensure that healthcare providers, patients, and the ...  The information update from ACOG and SMFM confirms ...
... MONTREAL, Oct. 13, 2011 A Medco Health Solutions, ... found that 38 percent of patients prescribed Plavix® (clopidogrel)—an ... and stroke—were also using another drug that would impede ... The analysis also showed that primary care physicians ...
Cached Medicine Technology:K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 2K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 3K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 4K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 5K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 6K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 7K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding Hydroxyprogesterone Caproate - FDA-Approved Makena™ and Compounded 17P 8Putting Gene Tests to Use: More Than a Third of Patients Cannot Properly Metabolize Plavix® 2Putting Gene Tests to Use: More Than a Third of Patients Cannot Properly Metabolize Plavix® 3Putting Gene Tests to Use: More Than a Third of Patients Cannot Properly Metabolize Plavix® 4
The all silicone construction of the shaft and neck flange provides the utmost in patient comfort. , ,The Aire-Cuf® tracheostomy tube offers a more traditional and familiar air-filled cuff desig...
... ISO termination for easy ventilator circuit attachment ... , ,Clearly the softer choice in ... ,The Portex® flexible disposable inner cannula ... chloride, providing a softer and more pliable ...
Indications For Usage: ,Bypass upper airway obstructions, provide long term ventilation, support and/or manage tracheal/bronchial secretions...
... Adult TRACH CARE Dual Lumen, ... at the patient end of ... Double Swivel Elbow and Direction ... port. Offers multiple tracheostomy sizes, ...
Medicine Products: